News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrion Pharmaceuticals, Inc. Finalises Its Phase III Development Program for Orazol(TM) in the USA



11/16/2010 9:40:59 AM

DUBLIN, Ireland, Nov. 16, 2010 (GLOBE NEWSWIRE) -- After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES